Browse studies

Find your next paid study

1 recruiting study matching your filters

ACR-2316-101: Phase 1/2 Study of ACR-2316 in Subjects With Advanced Solid Tumors

This is a first in-human, Open-label Phase 1/2 study to assess the safety and activity of ACR-2316 for the treatment of subjects with specific, histologically …

Specific Advanced Solid Tumors

Estimated

~$10 – $8,750

Acrivon TherapeuticsNCT06667141